NASDAQ · HUMA
Healthcare · Biotechnology
$0.47
Down-$0.01 (-1.53%)
Updated Oct 29, 2026, 7:17 PM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HUMA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 28, 2026
HUMA closed at $0.47 after 21 trading sessions, down 9.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 28, 2026 | $0.45 | $0.4794 | $0.4319 | $0.4701 | 2.66M |
| Oct 27, 2026 | $0.4142 | $0.4644 | $0.3941 | $0.4463 | 3.72M |
| Oct 26, 2026 | $0.46 | $0.4617 | $0.391 | $0.4006 | 3.98M |
| Oct 23, 2026 | $0.42 | $0.4398 | $0.3989 | $0.4354 | 2.61M |
| Oct 22, 2026 | $0.41 | $0.4199 | $0.40 | $0.4131 | 2.26M |
| Oct 21, 2026 | $0.41 | $0.42 | $0.3925 | $0.4112 | 4.18M |
| Oct 20, 2026 | $0.3921 | $0.4155 | $0.39 | $0.406 | 4.89M |
| Oct 19, 2026 | $0.4284 | $0.4394 | $0.3913 | $0.4011 | 4.69M |
| Oct 16, 2026 | $0.45 | $0.4597 | $0.4201 | $0.429 | 5.97M |
| Oct 15, 2026 | $0.3657 | $0.4456 | $0.3512 | $0.4395 | 20.79M |
| Oct 14, 2026 | $0.3634 | $0.3791 | $0.337 | $0.3541 | 5.43M |
| Oct 13, 2026 | $0.3896 | $0.3908 | $0.3555 | $0.3589 | 12.4M |
| Oct 12, 2026 | $0.40 | $0.413 | $0.3868 | $0.3896 | 16.35M |
| Oct 9, 2026 | $0.44 | $0.449 | $0.391 | $0.4053 | 8.6M |
| Oct 8, 2026 | $0.4748 | $0.4799 | $0.4367 | $0.4471 | 5.49M |
| Oct 7, 2026 | $0.4792 | $0.4799 | $0.46 | $0.4723 | 3.91M |
| Oct 6, 2026 | $0.501 | $0.5095 | $0.4724 | $0.478 | 4.28M |
| Oct 5, 2026 | $0.52 | $0.5223 | $0.4848 | $0.50 | 6.45M |
| Oct 2, 2026 | $0.5061 | $0.5343 | $0.5032 | $0.5215 | 5.4M |
| Oct 1, 2026 | $0.52 | $0.5283 | $0.5007 | $0.5029 | 3M |
| Sep 30, 2026 | $0.54 | $0.548 | $0.5104 | $0.5177 | 5.75M |
The latest Smart Investors Daily articles mentioning HUMA.
Company
Market Activity
Research & News
HUMA research
Company profile and research snapshot.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Aug 13, 2026 | Benchmark | Speculative Buy | — |
| Jul 28, 2026 | BTIG | Buy | — |
| Jun 17, 2026 | TD Cowen | Buy | — |
| Jun 16, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Jun 19, 2026
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Benzinga · Jun 17, 2026
TD Cowen analyst Joshua Jennings maintains Humacyte (NASDAQ:HUMA) with a Buy and lowers the price target from $1.5 to $1.25.
SeekingAlpha · Mar 6, 2026
Humacyte, Inc. (HUMA) TD Cowen 46th Annual Health Care Conference March 4, 2026 10:30 AM ESTCompany ParticipantsLaura Niklason - Founder, President, CEO...
Benzinga · Feb 19, 2026
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning HUMA.
